BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol. 2015;114:289-295. [PMID: 25497556 DOI: 10.1016/j.radonc.2014.11.033] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Mizuhata M, Takamatsu S, Shibata S, Bou S, Sato Y, Kawamura M, Asahi S, Tameshige Y, Maeda Y, Sasaki M, Kumano T, Kobayashi S, Yamamoto K, Tamamura H, Gabata T. Respiratory-gated Proton Beam Therapy for Hepatocellular Carcinoma Adjacent to the Gastrointestinal Tract without Fiducial Markers. Cancers (Basel) 2018;10:E58. [PMID: 29466294 DOI: 10.3390/cancers10020058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
2 Lariviere MJ, Santos PMG, Hill-kayser CE, Metz JM. Proton Therapy. Hematology/Oncology Clinics of North America 2019;33:989-1009. [DOI: 10.1016/j.hoc.2019.08.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kim DY, Park JW, Kim TH, Kim BH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim CM. Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother Oncol. 2017;122:122-129. [PMID: 28034460 DOI: 10.1016/j.radonc.2016.12.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
4 Kim TH, Park JW, Kim BH, Kim DY, Moon SH, Kim SS, Lee JH, Woo SM, Koh YH, Lee WJ, Kim CM. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017;9:4034-4043. [PMID: 29423102 DOI: 10.18632/oncotarget.23428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
5 Fukumitsu N, Okumura T, Takizawa D, Numajiri H, Ohnishi K, Mizumoto M, Aihara T, Ishikawa H, Tsuboi K, Sakurai H. Proton beam therapy for liver metastases from gastric cancer. J Radiat Res. 2017;58:357-362. [PMID: 27974509 DOI: 10.1093/jrr/rrw102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
6 Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:701-17. [PMID: 33012454 DOI: 10.1016/j.cld.2020.07.006] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Choi C, Son A, Lee GH, Shin SW, Park S, Ahn SH, Chung Y, Yu JI, Park HC. Targeting DNA-dependent protein kinase sensitizes hepatocellular carcinoma cells to proton beam irradiation through apoptosis induction. PLoS One 2019;14:e0218049. [PMID: 31194786 DOI: 10.1371/journal.pone.0218049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
8 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
9 Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J. 2016;34:160-167. [PMID: 27730805 DOI: 10.3857/roj.2016.01970] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
10 Oh D. Proton therapy: the current status of the clinical evidences. Precis Future Med 2019;3:91-102. [DOI: 10.23838/pfm.2019.00058] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, Seong J. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81-87. [PMID: 30773192 DOI: 10.1016/j.radonc.2018.12.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
12 McKinley SK, Chawla A, Ferrone CR. Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options. Surg Oncol Clin N Am 2019;28:745-62. [PMID: 31472917 DOI: 10.1016/j.soc.2019.06.009] [Reference Citation Analysis]
13 Spychalski P, Kobiela J, Antoszewska M, Błażyńska-Spychalska A, Jereczek-Fossa BA, Høyer M. Patient specific outcomes of charged particle therapy for hepatocellular carcinoma - A systematic review and quantitative analysis. Radiother Oncol 2019;132:127-34. [PMID: 30825961 DOI: 10.1016/j.radonc.2018.12.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
14 Fukumitsu N, Okumura T, Numajiri H, Takizawa D, Ohnishi K, Mizumoto M, Aihara T, Ishikawa H, Tsuboi K, Sakurai H. Follow-up study of liver metastasis from breast cancer treated by proton beam therapy. Mol Clin Oncol 2017;7:56-60. [PMID: 28685076 DOI: 10.3892/mco.2017.1283] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
15 Hasan S, Abel S, Verma V, Webster P, Arscott WT, Wegner RE, Kirichenko A, Simone CB 2nd. Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation. J Gastrointest Oncol 2019;10:999-1009. [PMID: 31602338 DOI: 10.21037/jgo.2019.08.03] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
16 Durante M. Charged particles for liver cancer. Ann Transl Med 2015;3:363. [PMID: 26807418 DOI: 10.3978/j.issn.2305-5839.2015.12.32] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
18 Yamaguchi H, Honda M, Hamada K, Kobayashi H, Todate Y, Seto I, Takayama K, Suzuki M, Wada H, Kikuchi Y, Murakami M. The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients. Jpn J Clin Oncol 2020;50:903-8. [PMID: 32363379 DOI: 10.1093/jjco/hyaa052] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Feuvret L, Calugaru V, Ferrand R. Hadronthérapie : quelle place et quelles perspectives en 2015 ? Cancer/Radiothérapie 2015;19:519-25. [DOI: 10.1016/j.canrad.2015.07.151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Roeder F, Lehner B, Saleh-ebrahimi L, Hensley FW, Ulrich A, Alldinger I, Mechtersheimer G, Huber PE, Krempien R, Bischof M, Debus J, Uhl M. Intraoperative electron radiation therapy combined with external beam radiation therapy and limb sparing surgery in extremity soft tissue sarcoma: a retrospective single center analysis of 183 cases. Radiotherapy and Oncology 2016;119:22-9. [DOI: 10.1016/j.radonc.2015.11.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
21 Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. Radiotherapy and Oncology 2018;129:112-22. [DOI: 10.1016/j.radonc.2017.11.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
22 Rim CH, Yoon WS. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials. Onco Targets Ther. 2018;11:2865-2874. [PMID: 29844684 DOI: 10.2147/ott.s164651] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
23 Keane FK, Hong TS. Charged particle therapy for hepatocellular carcinoma: a commentary on a recently published meta-analysis. Ann Transl Med 2015;3:365. [PMID: 26807420 DOI: 10.3978/j.issn.2305-5839.2015.12.36] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Long J, Zheng J, Sun B, Lu N. Microwave ablation of hepatocellular carcinoma with portal vein tumor thrombosis after transarterial chemoembolization: a prospective study. Hepatol Int 2016;10:175-84. [DOI: 10.1007/s12072-015-9673-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
25 Fukumitsu N, Nitta K, Terunuma T, Okumura T, Numajiri H, Oshiro Y, Ohnishi K, Mizumoto M, Aihara T, Ishikawa H, Tsuboi K, Sakurai H. Registration error of the liver CT using deformable image registration of MIM Maestro and Velocity AI. BMC Med Imaging 2017;17:30. [PMID: 28472925 DOI: 10.1186/s12880-017-0202-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
26 Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135-144. [PMID: 30773180 DOI: 10.1016/j.radonc.2018.12.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
27 Durante M, Debus J, Loeffler JS. Physics and biomedical challenges of cancer therapy with accelerated heavy ions. Nat Rev Phys 2021;3:777-90. [PMID: 34870097 DOI: 10.1038/s42254-021-00368-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
29 Schaub SK, Hartvigson PE, Lock MI, Høyer M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS, Apisarnthanarax S. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies. Technol Cancer Res Treat 2018;17:1533033818790217. [PMID: 30068240 DOI: 10.1177/1533033818790217] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
30 Lewis S, Barry A, Hawkins M. Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.02.021] [Reference Citation Analysis]
31 Kim BK, Kim DY, Byun HK, Choi HJ, Beom SH, Lee HW, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 2020;107:106-15. [PMID: 32084526 DOI: 10.1016/j.ijrobp.2020.01.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
32 Wang L, Ke Q, Huang Q, Shao L, Chen J, Wu J. Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. International Journal of Hyperthermia 2020;37:1313-21. [DOI: 10.1080/02656736.2020.1843719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Perkó Z, Bortfeld T, Hong T, Wolfgang J, Unkelbach J. Derivation of mean dose tolerances for new fractionation schemes and treatment modalities. Phys Med Biol 2018;63:035038. [PMID: 29099720 DOI: 10.1088/1361-6560/aa9836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Yu JI, Park HC. Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2016; 22(30): 6851-6863 [PMID: 27570422 DOI: 10.3748/wjg.v22.i30.6851] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
35 Kim N, Cheng J, Huang WY, Kimura T, Zeng ZC, Lee VHF, Kay CS, Seong J. Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study. Int J Radiat Oncol Biol Phys 2021;109:464-73. [PMID: 33229165 DOI: 10.1016/j.ijrobp.2020.09.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
36 Sun J, Wang Z, Sheng Y, Ming X, Jiang GL, Wang W. Indications of IMRT, PRT and CIRT for HCC from comparisons of dosimetry and normal tissue complication possibility. Strahlenther Onkol 2021. [PMID: 34618172 DOI: 10.1007/s00066-021-01854-6] [Reference Citation Analysis]
37 Mohamad O, Yamada S, Durante M. Clinical Indications for Carbon Ion Radiotherapy. Clinical Oncology 2018;30:317-29. [DOI: 10.1016/j.clon.2018.01.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
38 Hong J, Cao L, Xie H, Liu Y, Yu J, Zheng S. Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis. Hepatobiliary Surg Nutr 2021;10:623-30. [PMID: 34760966 DOI: 10.21037/hbsn.2020.03.15] [Reference Citation Analysis]
39 Nakamura M, Fukumitsu N, Kamizawa S, Numajiri H, Nemoto Murofushi K, Ohnishi K, Aihara T, Ishikawa H, Okumura T, Tsuboi K, Sakurai H. A validated proton beam therapy patch-field protocol for effective treatment of large hepatocellular carcinoma. J Radiat Res 2018;59:632-8. [PMID: 30085200 DOI: 10.1093/jrr/rry056] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
40 Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 2018;9:962-71. [PMID: 30505599 DOI: 10.21037/jgo.2017.11.07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
41 Nickoloff JA. Photon, light ion, and heavy ion cancer radiotherapy: paths from physics and biology to clinical practice. Ann Transl Med 2015;3:336. [PMID: 26734646 DOI: 10.3978/j.issn.2305-5839.2015.12.18] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
42 Tsai CL, Hsu FM, Cheng JC. How to Improve Therapeutic Ratio in Radiotherapy of HCC. Liver Cancer. 2016;5:210-220. [PMID: 27493896 DOI: 10.1159/000367767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
43 Aznar M, Méndez Romero A, Heijmen BJ. The role of technology in clinical trials using stereotactic body radiotherapy. Br J Radiol 2017;90:20160930. [PMID: 28055252 DOI: 10.1259/bjr.20160930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
44 Mohamad O, Sishc BJ, Saha J, Pompos A, Rahimi A, Story MD, Davis AJ, Kim DWN. Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair. Cancers (Basel) 2017;9:E66. [PMID: 28598362 DOI: 10.3390/cancers9060066] [Cited by in Crossref: 73] [Cited by in F6Publishing: 52] [Article Influence: 14.6] [Reference Citation Analysis]
45 Yamazaki H, Nakamura S, Suzuki G, Aibe N, Yoshida K. Superiority of charged particle therapy in treatment of hepatocellular carcinoma (Regarding Qi W.X. et al. charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: A systematic review and meta-analysis). Radiother Oncol 2016;118:420. [PMID: 26597232 DOI: 10.1016/j.radonc.2015.08.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Méndez Romero A, de Man RA. Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care. Best Pract Res Clin Gastroenterol 2016;30:603-16. [PMID: 27644908 DOI: 10.1016/j.bpg.2016.06.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
47 Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH. Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys 2017;99:667-76. [PMID: 29280461 DOI: 10.1016/j.ijrobp.2017.06.2450] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
48 Dionisi F, Brolese A, Siniscalchi B, Giacomelli I, Fracchiolla F, Righetto R, Morganti AG, Pravadelli C, Avancini I, Rozzanigo U, Mattiuzzi A, Frisinghelli M, Pertile R, Ciarleglio FA, Vitale A, Schwarz M, Amichetti M. Clinical results of active scanning proton therapy for primary liver tumors. Tumori 2021;107:71-9. [PMID: 32648818 DOI: 10.1177/0300891620937809] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Hwang EJ, Gorayski P, Le H, Hanna GG, Kenny L, Penniment M, Buck J, Thwaites D, Ahern V. Particle therapy toxicity outcomes: A systematic review. J Med Imaging Radiat Oncol 2020;64:725-37. [PMID: 32421259 DOI: 10.1111/1754-9485.13036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Patel CM, Wadas TJ, Shiozawa Y. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases. Molecules 2021;26:2162. [PMID: 33918705 DOI: 10.3390/molecules26082162] [Reference Citation Analysis]
51 Li Z, Li Q, Wang X, Li S, Chen W, Jin X, Liu X, Dai Z, Liu X, Zheng X, Li P, Zhang H, Zhang Q, Luo H, Liu R. Carbon Ion Radiotherapy Acts as the Optimal Treatment Strategy for Unresectable Liver Cancer During the Coronavirus Disease 2019 Crisis. Front Public Health 2021;9:767617. [PMID: 34957022 DOI: 10.3389/fpubh.2021.767617] [Reference Citation Analysis]
52 Kim TH, Lee KS, Sim SH, Kim YJ, Kim DY, Chae H, Lee EG, Han JH, Jung SY, Lee S, Kang HS, Lee ES. Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer. Front Oncol 2021;11:783327. [PMID: 34804986 DOI: 10.3389/fonc.2021.783327] [Reference Citation Analysis]
53 Cerrito L, Annicchiarico BE, Iezzi R, Gasbarrini A, Pompili M, Ponziani FR. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol 2019; 25(31): 4360-4382 [PMID: 31496618 DOI: 10.3748/wjg.v25.i31.4360] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 20] [Article Influence: 9.7] [Reference Citation Analysis]
54 Durante M, Paganetti H. Nuclear physics in particle therapy: a review. Rep Prog Phys 2016;79:096702. [DOI: 10.1088/0034-4885/79/9/096702] [Cited by in Crossref: 126] [Cited by in F6Publishing: 85] [Article Influence: 21.0] [Reference Citation Analysis]
55 Rim CH, Yim HJ, Park S, Seong J. Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta-analyses. J Med Imaging Radiat Oncol. 2019;63:812-821. [PMID: 31482683 DOI: 10.1111/1754-9485.12948] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
56 Price RG, Apisarnthanarax S, Schaub SK, Nyflot MJ, Chapman TR, Matesan M, Vesselle HJ, Bowen SR. Regional Radiation Dose-Response Modeling of Functional Liver in Hepatocellular Carcinoma Patients With Longitudinal Sulfur Colloid SPECT/CT: A Proof of Concept. International Journal of Radiation Oncology*Biology*Physics 2018;102:1349-56. [DOI: 10.1016/j.ijrobp.2018.06.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Mathew AS, Atenafu EG, Owen D, Maurino C, Brade A, Brierley J, Dinniwell R, Kim J, Cho C, Ringash J, Wong R, Cuneo K, Feng M, Lawrence TS, Dawson LA. Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. Eur J Cancer 2020;134:41-51. [PMID: 32460180 DOI: 10.1016/j.ejca.2020.04.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
58 Zhang H, Chang N, Han T, Ma S, Qu G, Liu H, Sun C, Cheng C, Zhou Q, Sun Y. Radiofrequency ablation versus stereotactic body radiotherapy for hepatocellular carcinoma: a meta-analysis. Future Oncol 2021. [PMID: 34278818 DOI: 10.2217/fon-2021-0263] [Reference Citation Analysis]
59 Benson AB 3rd, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017;15:563-573. [PMID: 28476736 DOI: 10.6004/jnccn.2017.0059] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 31.0] [Reference Citation Analysis]
60 Kobashi K, Prayongrat A, Kimoto T, Toramatsu C, Dekura Y, Katoh N, Shimizu S, Ito YM, Shirato H. Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy. J Radiat Res 2018;59:i50-7. [PMID: 29538699 DOI: 10.1093/jrr/rry018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
61 Yu JI, Park JW, Park HC, Yoon SM, Lim DH, Lee JH, Lee HC, Kim SW, Kim JH. Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study. Radiother Oncol. 2016;118:408-415. [PMID: 26830695 DOI: 10.1016/j.radonc.2015.11.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
62 Choi SH, Seong J. Strategic Application of Radiotherapy for Hepatocellular Carcinoma. Clin Mol Hepatol. 2018; Epub ahead of print. [PMID: 29439305 DOI: 10.3350/cmh.2017.0073] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
63 Cheng CW, Machtay M, Dorth J, Sergeeva O, Xia H, Manaspon C, Wu H, Iyer R, Sexton S, Xin W, Exner AA, Lee Z. Delayed response to proton beam treatment of hepatocellular carcinoma. BJR Case Rep. 2020;6:20180125. [PMID: 32201597 DOI: 10.1259/bjrcr.20180125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Kim TH, Park JW, Kim BH, Oh ES, Youn SH, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY. Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Front Oncol 2020;10:542. [PMID: 32411594 DOI: 10.3389/fonc.2020.00542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
65 Shinoto M, Ebner DK, Yamada S. Particle Radiation Therapy for Gastrointestinal Cancers. Curr Oncol Rep 2016;18:17. [PMID: 26849660 DOI: 10.1007/s11912-016-0499-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
66 Takamatsu S, Yamamoto K, Maeda Y, Kawamura M, Shibata S, Sato Y, Terashima K, Shimizu Y, Tameshige Y, Sasaki M, Asahi S, Kondou T, Kobayashi S, Matsui O, Gabata T. Evaluation of Focal Liver Reaction after Proton Beam Therapy for Hepatocellular Carcinoma Examined Using Gd-EOB-DTPA Enhanced Hepatic Magnetic Resonance Imaging. PLoS One 2016;11:e0167155. [PMID: 27907063 DOI: 10.1371/journal.pone.0167155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]